| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
TLR7 agonist 1 targets Toll-like receptor 7 (TLR7), a pattern recognition receptor that plays a critical role in innate immunity. TLR7 recognizes single-stranded RNA and activates signaling pathways leading to the production of type I interferons and pro-inflammatory cytokines. The compound acts as a potent and selective TLR7 agonist with an IC₅0 of 90 nM. By activating TLR7, it enhances antiviral and antitumor immune responses through NF-kappaB and interferon pathways. TLR7 is a validated target for immunotherapy.
|
|---|---|
| ln Vitro |
In vitro, TLR7 agonist 1 is a potent and selective TLR7 agonist with an IC₅0 of 90 nM. It activates TLR7 signaling, leading to the production of type I interferons and pro-inflammatory cytokines. The compound enhances antiviral and antitumor immune responses. Its potent and selective activity makes it a valuable tool for studying TLR7 biology and for developing immunomodulatory therapies. TLR7 agonist 1 has immunomodulatory and anticancer effects.
|
| ln Vivo |
In vivo, TLR7 agonist 1 is an orally available endogenous interferon (IFN-alpha) inducer in mice. Pharmacokinetic and pharmacodynamic studies have highlighted its potential as an orally active immunomodulatory agent. The compound's ability to induce IFN-alpha production makes it a promising candidate for antiviral and antitumor immunotherapy. Further in vivo studies are needed to fully characterize its efficacy, safety, and pharmacokinetic profile in various disease models.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, TLR7 agonist 1 can be evaluated using TLR7 reporter assays or binding studies. The compound is incubated with cells expressing TLR7 and a reporter gene (such as NF-kappaB or interferon-responsive luciferase) at various concentrations. TLR7 activation is quantified by measuring reporter activity. IC₅0 or EC₅0 values are determined from dose-response curves. Selectivity profiling against other TLR family members may be performed to confirm specificity. Standard assay conditions include appropriate cell culture media and incubation times.
|
| Cell Assay |
For in vitro cellular experiments, TLR7 agonist 1 is tested in immune cells such as dendritic cells, macrophages, or peripheral blood mononuclear cells to evaluate its effects on cytokine production and immune activation. Cells are cultured in appropriate media and treated with various concentrations of the compound. Cytokine production (such as IFN-alpha, TNF-alpha, and IL-6) is measured by ELISA or multiplex assays. The compound's effects on cell surface marker expression and immune cell activation are assessed by flow cytometry.
|
| Animal Protocol |
For in vivo animal experiments, TLR7 agonist 1 can be administered to rodents via oral gavage, taking advantage of its oral bioavailability. The compound's efficacy can be evaluated in models of viral infections or cancer. Typical dosing regimens may range from 1 to 50 mg/kg. Serum cytokine levels, immune cell activation, and disease progression are assessed. Pharmacodynamic markers such as IFN-alpha levels are measured. Tumor growth or viral load is monitored. Animal studies should follow appropriate ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TLR7 agonist 1 include oral bioavailability, supporting its administration via oral gavage in vivo. As a small molecule with a molecular weight of 363.46, it is likely to have reasonable absorption and distribution characteristics. Pharmacokinetic and pharmacodynamic studies have highlighted TLR7 agonist 1 as an orally available endogenous interferon (IFN-alpha) inducer in mice. Detailed parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance would need to be determined through comprehensive PK studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for TLR7 agonist 1 are limited, as it is primarily a research tool. As a TLR7 agonist, its toxicity would depend on the extent and duration of immune activation. Overactivation of TLR7 can lead to excessive inflammation and autoimmune-like effects. Comprehensive toxicology studies including acute and repeated-dose toxicity, immunotoxicity, and genotoxicity assessments would be needed for further development. Appropriate safety precautions should be taken when handling this compound.
|
| References | |
| Additional Infomation |
TLR7 agonist 1 is a research compound used to study TLR7 biology and develop immunomodulatory therapies. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a potent, selective, and oral TLR7 agonist with an IC₅0 of 90 nM that enhances antiviral and antitumor immune responses.
|
| Molecular Formula |
C21H25N5O
|
|---|---|
| Molecular Weight |
363.46
|
| Exact Mass |
363.205
|
| CAS # |
2178156-33-5
|
| PubChem CID |
137628641
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
468
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1C=CC=CC=1[C@H](C)NC(=O)C1C=CC=C2C=1C(=NC(N)=N2)NCCCC
|
| InChi Key |
WDFAZLUMAXOURM-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C21H25N5O/c1-3-4-13-23-19-18-16(11-8-12-17(18)25-21(22)26-19)20(27)24-14(2)15-9-6-5-7-10-15/h5-12,14H,3-4,13H2,1-2H3,(H,24,27)(H3,22,23,25,26)/t14-/m0/s1
|
| Chemical Name |
2-amino-4-(butylamino)-N-[(1S)-1-phenylethyl]quinazoline-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~275.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7513 mL | 13.7567 mL | 27.5133 mL | |
| 5 mM | 0.5503 mL | 2.7513 mL | 5.5027 mL | |
| 10 mM | 0.2751 mL | 1.3757 mL | 2.7513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
